SinoMab BioScience EV / EBITDA
Was ist das EV / EBITDA von SinoMab BioScience?
EV / EBITDA von SinoMab BioScience Limited ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit ev / ebitda ähnlich SinoMab BioScience
- Novavax hat EV / EBITDA von N/A
- Cazaly Resources hat EV / EBITDA von N/A
- DC Acquisition hat EV / EBITDA von N/A
- Macarthur Minerals hat EV / EBITDA von N/A
- Sierra Madre Gold and Silver hat EV / EBITDA von N/A
- Rathdowney Resources hat EV / EBITDA von N/A
- SinoMab BioScience hat EV / EBITDA von N/A
- Big Dougie Capital hat EV / EBITDA von N/A
- Income Trust hat EV / EBITDA von N/A
- Aloro Mining hat EV / EBITDA von N/A
- Manganese X hat EV / EBITDA von N/A
- Coho Collective Kitchens hat EV / EBITDA von N/A
- Viva Gold hat EV / EBITDA von N/A